English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/200954
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis

AuthorsLuque, Ana; Serrano, Inmaculada; Ripoll, Èlia; Malta, Catarina; Gomá, Montserrat; Blom, Anna M.; Grinyó, Josep María; Rodríguez de Córdoba, Santiago ; Torras, Joan; Aran, Josep M.
KeywordsC4BP(β−)
Dendritic cells
Ectopic lymphoid structures
Immunomodulation
Inflammation
Lupus nephritis
Issue Date6-Nov-2019
PublisherElsevier
CitationKidney Int S0085-2538(19)31049-X (2019)
AbstractLupus nephritis is a chronic autoimmune-inflammatory condition that can lead to end-stage kidney disease. Presently available immunosuppressive treatments for lupus nephritis are suboptimal and can induce significant side effects. Recently, we characterized a novel immunomodulatory activity of the minor isoform of the classical pathway complement inhibitor, C4BP(β-). We show here that C4BP(β-) treatment prevented the development of proteinuria and albuminuria, decreased significantly the formation of anti-dsDNA antibodies and, locally, mitigated renal glomerular IgG and C3 deposition and generation of apoptotic cells. There was a consequent histological improvement and increased survival in lupus-prone mice. The therapeutic efficacy of C4BP(β-) was analogous to that of the broad-acting immunosuppressant cyclophosphamide. Remarkably, a comparative transcriptional profiling analysis revealed that the kidney gene expression signature resulting from C4BP(β-) treatment turned out to be 10 times smaller than that induced by cyclophosphamide treatment. C4BP(β-) immunomodulation induced significant downregulation of transcripts relevant to lupus nephritis indicating immunopathogenic cell infiltration, including activated T cells (Lat), B cells (Cd19, Ms4a1, Tnfrsf13c), inflammatory phagocytes (Irf7) and neutrophils (Prtn3, S100a8, S100a9). Furthermore, cytokine profiling and immunohistochemistry confirmed that C4BP(β-), through systemic and local CXCL13 downregulation, was able to prevent ectopic lymphoid structures neogenesis in aged mice with lupus nephritis. Thus, due to its anti-inflammatory and immunomodulatory activities and high specificity, C4BP(β-) could be considered for further clinical development in patients with systemic lupus erythematosus.
Publisher version (URL)https://doi.org/10.1016/j.kint.2019.10.016
URIhttp://hdl.handle.net/10261/200954
DOI10.1016/j.kint.2019.10.016
ISSN0085-2538
E-ISSN1523-1755
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
restringido.pdfRestringido20,59 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.